

A Bioinformatic Approach for COVID-19 Spike Glycoprotein Deactivation by Chemical Modification of Asparagine and Lysine Residues *via* Vitamin B6 and Vitamin C

Homa Torabizadeh*

Department of Chemical Technologies, Iranian Research Organization for Science and Technology (IROST), Food Science and Technology Group, Mojtama Asre Enghelab Building, Shahid Ehsanirad Street, 33535111, Tehran, Iran

ABSTRACT

To invade human cells, COVID-19 uses its spike glycoprotein as the major surface protein. This glycoprotein can be inactivated through chemical modification of surface accessible asparagine and lysine residues by vitamin B6 (pyridoxal-5'-phosphate, PLP) and vitamin C (ascorbic acid). This reversible reaction leading to the formation of a Schiff base (aldimine), and consequent reduction by ascorbate lead to form a stable phosphopyridoxyl-lysyl or asparagyl covalent bonds. For this purpose, at first, the spike glycoprotein sequences in similar proteins with 100% identity was specified by using of UniProtKB that is located at the ExpASY server. All of these proteins have a 1,255 length and 139,125 Mass (Da) respectively. Then, GetArea software was used for accessible surface area determination of each sequence by employing of PDB files that is reserved at PDB website. The results revealed that, 51 out of 81 (for asparagine) and 22 out of 48 (for lysine) are accessible for PLP reaction. Thus, terminal amino groups (NH₂) of asparagine and lysine can react with PLP and produce Schiff base bond and then it can be converted to a strong covalent bond by ascorbic acid reduction. In this way, attachment and fusion process can be prevented. This may be a way for vaccine and drug preparation.

Keywords: Spike glycoproteins; COVID-19; Vitamin B6; Chemical modification; Bioinformatics

INTRODUCTION

Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was determined to be the agent of coronavirus disease 2019 (COVID-19). The virus belongs to the Betacoronavirus genus of the Coronaviridae family, which also includes Severe Acute Respiratory Syndrome Coronavirus 1 (SARS-CoV-1) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [1]. The pandemic caused by the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) has generated global concern given its rapid spread in multiple countries with fatal progression in a considerable proportion of COVID-19 patients [1,2]. SARS-CoV-2 is an enveloped virus with a positive-sense, single-stranded RNA genome with sizes ranging from 26-32 kilobases in length [3]. The SARS-CoV-2 genome encodes four major structural glycoproteins to produce a structurally complete viral particle which includes the nucleocapsid, membrane, envelope, and

spike proteins (S) [4]. This kind of particle can enter host cells by binding the viral surface spike glycoprotein to angiotensin-converting enzyme 2 [5]. The spike glycoproteins forms homotrimers protruding from the viral surface; especially, the spike 1 surface unit allows the attachment of the virus to cellular receptors [4,5]. By using of several bioinformatics tools and biological databases functional analysis for prediction of spike glycoprotein inactivation can be possible. Bioinformatics study is a strong tool specified in sortation, organization, and process large amounts of available data generated from other experiments to provide a large-scale immunological platform within a limited time. Since the virus genome and its protein sequences information are available, the presented epitopes and the virus characteristics could be predicted by *in silico* analysis, which significantly accelerates the progress of vaccine development [6-10].


Correspondence to: Homa Torabizadeh, Iranian Research Organization for Science and Technology (IROST), Department of Chemical Technologies, Food Science and Technology Group, Mojtama Asre Enghelab Building, Shahid Ehsanirad Street, 33535111, Tehran, Iran, E-mail: htoraby@alumni.ut.ac.ir

Received: 14-Jun-2022, Manuscript No. JPB-22-17927; **Editor assigned:** 17-Jun-2022, PreQC No. JPB-22-17927 (PQ); **Reviewed:** 01-Jul-2022, QC No. JPB-22-17927; **Revised:** 08-Jul-2022, Manuscript No. JPB-22-17927 (R); **Published:** 15-Jul-2022, DOI: 10.35248/0974-276X.22.15.591

Citation: Torabizadeh H (2022) A Bioinformatic Approach for COVID-19 Spike Glycoprotein Deactivation by Chemical Modification of Asparagine and Lysine Residues *via* Vitamin B6 and Vitamin C. J Proteomics Bioinform.15:591


Copyright: © 2022 Torabizadeh H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The SARS-CoV S glycoprotein is synthesized as a 1255 amino acid polypeptide precursor on the Rough Endoplasmic Reticulum (RER) [11]. The unprocessed precursor harbors an Endoplasmic Reticulum (ER) signal sequence (chain 1-13) located at the N terminus, which targets the S glycoprotein to the RER membrane and is removed by cellular signal peptidases in the lumen of the ER [12,13]. In the trans-Golgi network, the SARS-CoV-2 S glycoprotein is proteolytically cleaved by cellular furin or furin-like proteases at the S1/S2 cleavage site, comprising multiple arginine residues that are not found in the closely related SARS-CoV [14,15]. Cleavage at the S1/S2 site yields a surface subunit S1, which attaches the virus to the host cell surface receptor, and a transmembrane subunit S2, which mediates the fusion of viral and host cell membranes [16]. The S1 and S2 subunits remain associated through noncovalent interactions in a metastable prefusion state [17]. Furin-like cleavage is essential for the S-protein mediated cell-cell fusion and viral infectivity, and is required for efficient SARS-CoV-2 infection of human lung cells [14] and airway epithelial cells [18]. Membrane fusion and viral entry of SARS-CoV-2 is initiated by binding of RBD in the viral S glycoprotein transiently sampling the functional conformation to ACE2 on the surface of target cells [19]. These spike glycoproteins are included; Spike protein S1, that, attaches the virion to the cell membrane by interacting with host receptor, initiating the infection (By similarity). Binding to human ACE2 and CLEC4M/DC-SIGNR receptors and internalization of the virus into the endosomes of the host cell induces conformational changes in the S glycoprotein. Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes. Spike protein S2 which, mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell. membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. UniRule annotation. Spike protein S2' that, acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis. S1, S2, and S2' locations that can link by glycosylation *via* N-linked of asparagine (GlcNAc...) and host membrane cell (Figure 1) [19].



This study is aimed at prediction of Spike SARS-CoV-2 glycoproteins inactivation by chemical modification of asparagine and lysine residues *via* covalently binding to pyridoxal-5'-phosphate (vitamin B6) and then reduction of Schiff

base formed by vitamin C. Due to the binding of spike glycoproteins to ACE2 human cells, which is mostly done through asparagine, the main emphasis in this study is on asparagine roots (Figure 2).



METHODOLOGY

The amino acid sequences of SARS-CoV spike glycoprotein and docking was gained from UniProtKB and Swiss-Dock that are located at the ExPASy server (Swiss Bioinformatics Resource Portal). The structure of glycoproteins as well as, pdb data files were resulted from The Protein Data Bank (PDB; <http://www.rcsb.org/pdb/>). Calculation of Solvent Accessible Surface Area was performed by GETAREA from sealy center for structural biology, university of Texas medical branch, Galveston. TX 77555. Docking of spike glycoprotein with pyridoxal-5'-phosphate (as a ligand) was carried out by using of SwissDock that is located at the ExPASy server.

Spike glycoprotein S1, S2, and S2' sequences

Based on information that is located at UniProtKB (ExPASy server) for Spike glycoprotein, P59594|SPIKE_CVHSA Spike glycoprotein OS=Human SARS coronavirus, the sequence lengths for signal peptides, S1, S2, and S2' are as follow in Figure 3.

Sequences				
110	20	30	40	50
MEFLLEFLFL	TSGSDLDRCT	TEDDVQAPV	TQRTSSMRGV	YYPDEIFRSD
120	30	40	50	60
TLYLTDGLFL	PFYSVVTQGH	TIHTFGFNV	IFPRDGIYFA	ATEKSNVVRG
130	40	50	60	70
WVFGSTMRSP	SQSIVLIIHNS	TSVWIRACRF	ELCDEPFPAV	SKRMGTQTHF
140	50	60	70	80
MLPDAFATCF	FEYISDAFSL	DVSEKGGREF	HLREVPFQIK	DGFLVYVRSK
150	60	70	80	90
QFIDAVRFLCF	SOEFLPLCF	KLPLGKQFSC	FRALITAFQK	AGDLDWQFSA
160	70	80	90	100
AYEVGVLKRT	TEMLKQYDSD	TIIDAVDQCSQ	IFLAELEKTV	KSEFIDIKGIV
170	80	90	100	110
QTSSEFLVQDS	GDVVFVDFEY	NLDFEGEYRE	ATKRFPSVQAW	REKIKISQVA
180	90	100	110	120
DYSVLYLQCF	ESTEKCYVGS	ATKLNGLDLS	RYVADSPFAK	GDDVROISVA
190	100	110	120	130
QTVGLADVRE	KLPPDDFEGY	LAWNTFLDIA	TSTGTGYNIS	KYLRRGKLDL
200	110	120	130	140
FERDLSVDFE	SPDGKCFTEP	ALUCYWFLEQ	YGFYTTGIG	VQPRVAVLVS
210	120	130	140	150
FELLEAPATV	QPKLSTDLI	KKOCVNFVRE	GLTGTQVLE	SKRFPQFQD
220	130	140	150	160
FGRDVSDFTD	SVRDPKTSFI	LDISPCSFEG	VSVITPQFSA	SSEVAVLQSD
230	140	150	160	170
VKCTDVSATL	HADQLPAWR	IYSTGKRVQD	TQAGLIGAE	HVPTSYECDD
240	150	160	170	180
FRAGTCASLY	HTVSELLSFR	GRFVAVYRIS	LEADSEIATL	FKTATITFEP
250	160	170	180	190
SISITTEPQY	VSMKATVYFS	EMKICGDYRE	CANLILQVRS	PKLTLRSLIS
260	170	180	190	200
NRGAISDQDF	REVPAGVQVQ	YKPTFLIKRQ	GRFESQIQIS	FLKPTKRIIS
270	180	190	200	210
EDLLEKQKVI	ADAGFMKQVQ	ECLGDIKARD	LICAGKRFEL	TVLPLFLTIS
280	190	200	210	220
MIAAYTAAVY	SGTATAGVFS	GAGAALIQIS	AMEMAYRQIK	IGVTQVNLIS
290	200	210	220	230
NFGIADLQVY	KALSOIQEEL	TTTSTALGKL	QDVVNSQADA	LNTLVRLISS
300	210	220	230	240
NFGAISVFLN	DILSRLDREY	AEVDIDRLTI	GRLOSQVQV	TOOLLRARIS
310	220	230	240	250
RASANLAATK	PAECVLDGSK	RVDFCGKGRH	LMSFPQAAFH	QVFLRNTVTA
320	230	240	250	260
PSRQKFTTA	MAICHEGKAA	FRPBGVYVRE	QTSWFITGRS	FFSPQITITL
330	240	250	260	270
NTFVAGSLIV	VIGLILQVQV	EPGLQKISSE	RESELEKQIS	HTSPDVLISD
340	250	260	270	280
ISGTEASLIV	VIGLILQVQV	VAKQLLEKIS	DLDGLKQVQV	YIKKQVWISD
350	260	270	280	290
FGIAGLIAVY	MVTLILLCQF	SCCSCLRGAC	SCGSCCKRDE	DDSEPVLRQV
360	270	280	290	300
KLHYT				

Figure 3: Schematic representation of the domain arrangement of the SARS-CoV-2 S protein precursor. SS, signal peptide; NTD: N-terminal domain; RBD: receptor-binding domain;

RBM: receptor-binding motif; SD1/2: subdomain 1 and 2; FP, fusion peptide; HR1, heptad repeat 1; CH, central helix; CD, connector domain; HR2, heptad repeat 2; TM, transmembrane domain; CT, cytoplasmic tail. Arrows denote protease cleavage sites [19]. ExPASy Code: P59594|SPIKE_CVHSA Spike glycoprotein OS=Human SARS coronavirus (Severe acute respiratory syndrome coronavirus) Length:1,255; Mass (Da):139,125; Total Asparagine residues (Asn, or N)=81(Table 1).

Solvent accessible surface area assessment by GETARE

For asparagine residues estimation that are located at the surface of spike glycoprotein and can be react with pyridoxal phosphate, the spike glycoprotein sequences were analysed by GETAREA software. For this reason,

Chains	Length (Amino acids)
Signal peptides, 1-13	13
Spike glycoprotein, 14-1255	1242
Spike protein S1 UniRule annotation, 14-667	654
Spike protein S2 UniRule annotation, 668-1255	588
Spike protein S2', 798-1255	458

Table 1: Spike glycoprotein sequences. Signal peptides, Spike protein S1, S2, and S2' chain and amino acid content.

Glycosylation regions by Asparagine at host cell membrane are present below:

Glycosylation 29 N-linked (GlcNAc...) asparagine
 Glycosylation 65 N-linked (GlcNAc...) asparagine
 Glycosylation 73 N-linked (GlcNAc...) asparagine
 Glycosylation 109 N-linked (GlcNAc...) asparagine
 Glycosylation 118 N-linked (GlcNAc...) asparagine
 Glycosylation 119 N-linked (GlcNAc...) asparagine
 Glycosylation 158 N-linked (GlcNAc...) asparagine
 Glycosylation 227 N-linked (GlcNAc...) asparagine
 Glycosylation 269 N-linked (GlcNAc...) asparagine
 Glycosylation 318 N-linked (GlcNAc...) asparagine
 Glycosylation 330 N-linked (GlcNAc...) asparagine
 Glycosylation 357 N-linked (GlcNAc...) asparagine
 Glycosylation 589 N-linked (GlcNAc...) asparagine
 Glycosylation 602 N-linked (GlcNAc...) asparagine
 Glycosylation 691 N-linked (GlcNAc...) asparagine
 Glycosylation 699 N-linked (GlcNAc...) asparagine
 Glycosylation 783 N-linked (GlcNAc...) asparagine
 Glycosylation 1056 N-linked (GlcNAc...) asparagine
 Glycosylation 1090 N-linked (GlcNAc...) asparagine
 Glycosylation 1116 N-linked (GlcNAc...) asparagine
 Glycosylation 1140 N-linked (GlcNAc...) asparagine
 Glycosylation 1155 N-linked (GlcNAc...) asparagine
 Glycosylation 1176 N-linked (GlcNAc...) asparagine

at first pdb format files of spike glycoproteins with pdb code 5WRG (method: Electron microscopy, Resolution: 4.30 Å, Uniprot: P59594) and 1WNC (method: X-Ray Diffraction, Resolution: 2.80 Å, Uniprot: P59594), that was placed in the PDB website were selected. Then, pdb format files were uploaded to GETAREA software with water Probe radius of 1.400 Å and the area/energy/residue was calculated. Afterwaeds, the total numbers of each amino acid, the number of amino acids available at the surface (out) and the number of amino acids within the spike glycoprotein molecule (In) were estimated.

Spike glycoprotein docking with pyridoxal-5'-phosphate

Docking of spike glycoprotein (pdb code: 1WNC) with pyridoxal-5'-phosphate was achieved by using of SwissDock (Docking of small ligands into protein molecules) that is located at the ExPASy server (Swiss Bioinformatics Resource Portal) (Table 2).

Amino acid	Total number	Accessibility	
		In	Out
THR	78	45	33
PHE	42	37	5
MET	12	11	1

LEU	60	54	6
LYS	48	26	22
TYR	34	29	5
ASP	60	36	24
GLU	23	12	11
ASN	81	30	51
GLY	46	33	13
ILE	42	35	7
VAL	57	49	8
ALA	52	40	12
CYS	37	37	0
SER	59	42	17
GLN	38	28	10
PRO	35	24	11
ARG	26	23	3
TRP	4	3	1
HIS	6	4	2

Table 2: Accessible surface area results for all 1255 amino acids (pdb: 5WRG).

Solvent accessible surface area assessment by GETARE

The results of GETAREA revealed that, among these 81 asparagine (Asn) residues that are present in the spike glycoprotein sequences, 51 Asn are at the surface of the protein molecule (Outer) and 30 Asn are within the protein structure. Hence, there is a highly chance for amino groups (NH₂) of Asparagine (Asn) reaction with pyridoxal-5'-phosphate and reduction of these schiff base by ascorbic acid (vitamin C) for producing covalently bonded pyridoxal phosphate to Asn residues and inactivation of reactive region of spike glycoproteins or inhibition of Glycosylation N-linked (GlcNAc...) asparagine with the host cells.

Spike glycoprotein docking with pyridoxal-5'-phosphate

The results of spike glycoprotein docking (1WNC) with pyridoxal-5'-phosphate as a ligands confirmed the results of Accessible Surface Area evaluations and implied that, pyridoxal phosphate can bind to the spike glycoprotein *via* asparagine residues that are present at the outer surface of this protein molecule (Figure 5) (Table 3).

RESULTS AND DISCUSSION

Spike glycoprotein S1, S2, and S2' sequences

Based on sequence data for spike glycoprotein (Uniprot code: P59594) that is located at UniprotKB at ExPASy server, Protein: (Spike glycoprotein, Gene: S, Organism: Human SARS coronavirus (SARS-CoV) (Severe acute respiratory syndrome coronavirus), there are 81 asparagine amino acid residues in the COVID-19 glycoprotein sequence that are highly reactive with pyridoxal-5'-phosphate. These asparagines are marked in green in sequence (Figure 4).




Figure 4: Spike glycoprotein (pdb: 5WRG). Asparagine residues are in green.

ASN Num	Accessibility	ASN Num	Accessibility	ASN Num	Accessibility	ASN Num	Accessibility
29	Out	330	Out	699	Out	1107	-
65	Out	347	Out	721	In	1116	Out
73	Out	357	Out	733	Out	1140	Out
78	Out	375	Out	746	In	1155	Out
96	Out	381	In	759	In	1160	Out
108	Out	409	In	783	In	1169	Out
109	Out	424	In	806	Out	1174	Out
118	Out	427	Out	827	In	1176	Out
119	Out	435	In	838	In	1176	Out
122	In	437	Out	889	Out		
129	In	457	Out	896	Out		
135	Out	473	Out	901	In		
155	In	479	Out	907	Out		
158	In	505	Out	910	Out		
178	In	522	Out	935	In		
189	In	526	In	937	In		
214	In	528	In	942	Out		
227	Out	530	In	951	In		
230	Out	589	Out	960	In		
269	Out	602	Out	1005	In		
281	Out	626	Out	1056	Out		
304	In	627	Out	1080	-		
318	Out	691	Out	1090	Out		
321	Out	692	Out	1101	Total ASN Number=81 residues		

Table 3: GETARE results for spike glycoprotein Asparagine residues.




Figure 5: Spike glycoprotein (pdb: 5WRG). Asparagine residues are in green.

CONCLUSION

Realizing every step during virus entry into the human cell and of virus replication and packaging could, in principle, be the aim of inhibitors. Identification of asparagine residues in reaction with human cell ACE2 by using of bioinformatic tools for inactivation of these residues by chemical modification with pyridoxal phosphate (vitamin B6) and ascorbic acid (vitamin C) will provide the insights to assist in the development of SARS-CoV-19 vaccines.

REFERENCES

1. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antivir Res.* 2020;176: 104742.
2. Beavis KG, Matushek SM, Abeleda APF, Hunt C, Gillen S, Moran A, et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. *J Clin Virol.* 2020;129: 104468.
3. Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395:497-506.
4. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell.* 2020;181: 281-292.
5. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. *Intensive Care Med.* 2020; 46: 586-590.
6. Chen H, Tang L, Yu X, Zhou J, Chang Y, Wu X. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. *Infect Dis Poverty* 2020;9(1): 1–10.
7. Kiyotani K, Toyoshima Y, Nemoto K, Nakamura Y. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2. *Eur J Hum Genet.* 2020; 65(7): 569–575.
8. Banerjee, S., Majumder, K., Gutierrez, G. J., Gupta, D., Mittal, (2020). Immuno-informatics approach for multi-epitope vaccine designing against SARS-CoV-2. *bioRxiv* 2020 ; 2007: 2023-2185.
9. Rakib, A., Sami, S. A., Mimi, N. J., Chowdhury, M. M., Eva, T. A., Nainu, F., et al. (2020). Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. *Comput Biol Med.* 2020; 124: 103967.
10. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more. *Arch Med Res.* 2020; 51: 585–586.
11. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J Med Virol.* 2020; 92:595–601.
12. Breitling J, Aeberli M. N-linked protein glycosylation in the endoplasmic reticulum. *Cold Spring Harb Perspect Biol.* 2013; 5:a013359.
13. Braakman I, Hebert DN. Protein folding in the endoplasmic reticulum. *Cold Spring Harb Perspect Biol.* 2013; 5:a013201.
14. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses.* 2012; 4:1011–33.
15. Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. *Life Sci.* 2020; 15: 257:118056.
16. Hoffmann M, Kleine-Weber H, Pohlmann SA. Multi-basic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. *Mol Cell.* 2020: 78:779–84 e5.
17. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res.* 2020; 176:104742.
18. Bestle D, Heindl MR, Limburg H, Pilgram O, Moulton H, Stein DA, et al. TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets. *Life Sci Alliance.* 2020 Sep; 3:e202000786.
19. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang, H. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. *Front Immunol.* 2020; 11: 576622.